Considering the recent discoveries; it would be a lot easier for a small company like RAC to commercialise an Anthracyclene/Decitabine/PD1 synergiser than a stand alone salvage chemotherapeutic or FTO inhibitor.
I still think we're gone shortly after any positive readouts in the EM AML/MDS trial (registered as a liquid tumour agent/Decitabine synergiser - not just one cancer indication).
RAC media coverage, page-720
-
- There are more pages in this discussion • 1,574 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.020(1.20%) |
Mkt cap ! $286.2M | |||
| Open | High | Low | Value | Volume |
| $1.68 | $1.68 | $1.61 | $177.8K | 108.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1100 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 4999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |